Halozyme Therapeutics Hits New 52-Week High of $84.38

Halozyme Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 84.38 on July 28, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated a remarkable 63.11% increase over the past year, significantly outperforming the S&P 500, which recorded a 16.26% gain during the same period. With a market capitalization of USD 7,273 million, Halozyme is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 11.00, indicating a favorable valuation compared to many peers in the industry. Additionally, the company boasts an impressive return on equity of 1,371.85%, reflecting its efficient use of shareholder funds. Despite a debt-to-equity ratio of 41.20 and a price-to-book ratio of 149.00, Halozyme's recent performance highlights its robust market position and operational effectiveness. The stock's previous 52-week low was recorded at USD 57.68, marking a significant upward trend in its valuation.